This technology has not been officially recognized in China, and there is no patented equipment. China has not passed the audit, and there is not enough foundation for the maturity of this technology. In addition, many third-party testing institutions operate privately, the market order is chaotic, and the country needs to be rectified. Moreover, the cost of this test is relatively expensive, and the results can be basically understood from Down's test. This way of inducing people to consume mostly satisfies commercial interests.

Everyone knows that noninvasive technology is a new technology in America. However, American medical care has not applied this technology to clinical diagnosis. Since the countries that invented this method failed to pass the examination, it is obvious that China has taken it as an American experiment, and it will even become a basis for this technology to pass the examination in the future. How unfair.

For the vast majority of pregnant women, the cost of testing this project is unbearable, usually thousands of dollars. And more than 99% of the test results are basically normal.

The two joint notices pointed out that the products and technologies related to gene sequencing, including prenatal genetic testing, belong to the field of contemporary cutting-edge technology research, involving ethics, privacy and protection of human genetic resources, biosafety, and technical management, price and quality supervision of gene diagnosis services in medical institutions.